Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals...
GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions in the European Union for two of its cancer medicines. The CHMP has issued a positive opinion for the authorisation of a new therapeutic...
GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions in the European Union for two of its cancer medicines. The CHMP has issued a positive opinion for the authorisation of a new therapeutic...
GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions in the European Union for two of its cancer medicines. The CHMP has issued a positive opinion for the authorisation of a new therapeutic...